You are here

  • Home
  • Archive
  • Volume 1, Issue 1
  • The H2 blocker famotidine suppresses progression of ossification of the posterior longitudinal ligament in a mouse model

Article Text

Article menu

Download PDFPDF

Spine
Concise report
The H2 blocker famotidine suppresses progression of ossification of the posterior longitudinal ligament in a mouse model
  1. Yujiro Maeda1,2,
  2. Kenichi Yamamoto1,2,
  3. Akira Yamakawa2,
  4. Hailati Aini3,
  5. Tsuyoshi Takato1,
  6. Ung-il Chung2,3 and
  7. Shinsuke Ohba2,3
  1. 1Department of Sensory and Motor System Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
  2. 2Division of Clinical Biotechnology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
  3. 3Department of Bioengineering, The University of Tokyo Graduate School of Engineering, Tokyo, Japan
  1. Correspondence to Dr Shinsuke Ohba; ohba{at}bineng.t.u-tokyo.ac.jp

Abstract

Background Ossification of the posterior longitudinal ligament (OPLL) of the spine is a common human myelopathy that leads to spinal cord compression. No disease-modifying drug for OPLL has been identified, whereas surgery and conservative management have been established.

Objectives To evaluate the therapeutic potential of the H2 blocker famotidine for ectopic ossification in the cervical spine in an OPLL mouse model.

Methods The H2 blocker famotidine was orally administered to Enpp1ttw/ttw mice, a model of OPLL, at either 4 or 15 weeks of age. Radiological and survival rate analyses were performed to assess the effects of famotidine on OPLL-like lesions and mortality in Enpp1ttw/ttw mice.

Results Oral administration of famotidine suppressed the progression of OPLL-like ectopic ossification and reduced mortality in Enpp1ttw/ttw mice when administration began at 4 weeks of age, early in the development of ossification.

Conclusions This study points to the use of famotidine as a disease-modifying drug for ectopic ossification of spinal soft tissue, including OPLL.

  • Orthopedic Surgery
  • Treatment
  • Tendinitis

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/rmdopen-2015-000068

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text